HRP20211710T1 - Site-specific conjugation of linker drugs to antibodies and resulting adcs - Google Patents

Site-specific conjugation of linker drugs to antibodies and resulting adcs Download PDF

Info

Publication number
HRP20211710T1
HRP20211710T1 HRP20211710TT HRP20211710T HRP20211710T1 HR P20211710 T1 HRP20211710 T1 HR P20211710T1 HR P20211710T T HRP20211710T T HR P20211710TT HR P20211710 T HRP20211710 T HR P20211710T HR P20211710 T1 HRP20211710 T1 HR P20211710T1
Authority
HR
Croatia
Prior art keywords
antibody
compounds according
cancer
image
compounds
Prior art date
Application number
HRP20211710TT
Other languages
Croatian (hr)
Inventor
Gerardus Joseph Andreas ARIAANS
Rudy Gerardus Elisabeth Coumans
Original Assignee
Byondis B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771151&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20211710(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byondis B.V. filed Critical Byondis B.V.
Publication of HRP20211710T1 publication Critical patent/HRP20211710T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Spojevi konjugata protutijela i lijeka pri čemu je lijek za povezivanje specifično konjugiran na IgG1 protutijelo kroz inženjeringom konstruirani cistein u navedenom protutijelu na poziciji 41 teškog lanca sukladno Kabat numeraciji, pri čemu navedeni lijek za povezivanje sadrži derivat duokarmicina.1. Antibody-drug conjugate compounds, wherein the coupling drug is specifically conjugated to the IgG1 antibody through an engineered cysteine in said antibody at position 41 of the heavy chain according to Kabat numbering, wherein said coupling drug contains a duocarmycin derivative. 2. Spojevi sukladno patentnom zahtjevu 1, još sadrži inženjeringom konstruirani cistein na poziciji 375 u Fc dijelu navedenog protutijela sukladno Eu numeraciji.2. Compounds according to patent claim 1, also contain engineered cysteine at position 375 in the Fc part of the said antibody according to Eu numbering. 3. Spojevi sukladno patentnom zahtjevu 1 ili 2 iz formule (I) [image] pri čemu n je 0-3, m predstavlja prosječan DAR između od 1 do 6, R1 je odabrano od [image] [image] y je 1-16, i R2 je odbrano od [image] 3. Compounds according to patent claim 1 or 2 from formula (I) [image] whereby n is 0-3, m represents the average DAR between 1 and 6, R1 is selected from [image] [image] y is 1-16, and R2 is defended from [image] 4. Spojevi sukladno patentnom zahtjevu 3, pri čemu n je 0-1, m predstavlja prosječan DAR od 1,5 do 2, R1 je [image] y je 1-4, i R2 je odbrano od [image] 4. Compounds according to patent claim 3, wherein n is 0-1, m represents an average DAR of 1.5 to 2, R1 is [image] y is 1-4, and R2 is defended from [image] 5. Spojevi sukladno bilo kojem od patentnih zahtjeva 1-4 od formule (II) [image] 5. Compounds according to any of claims 1-4 of formula (II) [image] 6. Spojevi sukladno bilo kojem od patentnih zahtjeva 1-5, pri čemu se navedeno protutijelo veže na ciljni antigen koji je eksprimiran u ili na membrani stanice neke stanice tumora i pri čemu navedeno protutijelo ta stanica inkorporira nakon vezivanja na navedeni cilj.6. Compounds according to any of claims 1-5, wherein said antibody binds to a target antigen that is expressed in or on the cell membrane of a tumor cell and wherein said antibody is incorporated by said cell after binding to said target. 7. Spojevi sukladno bilo kojem od patentnih zahtjeva 1-6, pri čemu je navedeno protutijelo anti-aneksin A1 protutijelo, anti-CD115 protutijelo, anti-CD123 protutijelo, anti-CLL-1 protutijelo, anti-c-MET protutijelo, anti-MUC1 protutijelo, anti- PSMA protutijelo, anti-5T4 protutijelo ili anti-TF protutijelo.7. Compounds according to any of claims 1-6, wherein said antibody is anti-annexin A1 antibody, anti-CD115 antibody, anti-CD123 antibody, anti-CLL-1 antibody, anti-c-MET antibody, anti- MUC1 antibody, anti-PSMA antibody, anti-5T4 antibody or anti-TF antibody. 8. Spojevi sukladno bilo kojem od patentnih zahtjeva 1 do 7, pri čemu je navedeno protutijelo anti-PSMA monoklonalno protutijelo ili anti-5T4 monoklonalno protutijelo.8. Compounds according to any one of claims 1 to 7, wherein said antibody is an anti-PSMA monoclonal antibody or an anti-5T4 monoclonal antibody. 9. Spojevi sukladno patentnom zahtjevu 8, pri čemu teški lanac navedenog anti- PSMA protutijela sadrži sekvencu aminokiseline iz SEK ID BR:2 i laki lanac navedenog anti-PSMA protutijela sadrži sekvencu aminokiseline iz SEK ID BR:5.9. Compounds according to claim 8, wherein the heavy chain of said anti-PSMA antibody contains the amino acid sequence from SEQ ID NO:2 and the light chain of said anti-PSMA antibody contains the amino acid sequence from SEQ ID NO:5. 10. Spojevi sukladno patentnom zahtjevu 8, pri čemu teški lanac navedenog anti-5T4 protutijela sadrži sekvencu aminokiseline iz SEK ID BR:8 i laki lanac navedenog anti-5T4 protutijela sadrži sekvencu aminokiseline iz SEK ID BR:11.10. Compounds according to claim 8, wherein the heavy chain of said anti-5T4 antibody contains the amino acid sequence from SEQ ID NO:8 and the light chain of said anti-5T4 antibody contains the amino acid sequence from SEQ ID NO:11. 11. Farmaceutski pripravak koji sadrži spojeve sukladno bilo kojem od patentnih zahtjeva 1-10 i jedan ili više farmaceutski prihvatljivih ekscipijensa, poželjno u obliku liofiliziranog praha.11. A pharmaceutical preparation containing compounds according to any of claims 1-10 and one or more pharmaceutically acceptable excipients, preferably in the form of a lyophilized powder. 12. Spojevi sukladno bilo kojem od patentnih zahtjeva 1-10 ili farmaceutski pripravak sukladno patentnom zahtjevu 11, za uporabu kao lijek.12. Compounds according to any one of patent claims 1-10 or a pharmaceutical preparation according to patent claim 11, for use as a medicine. 13. Spojevi sukladno bilo kojem od patentnih zahtjeva 1-10 ili farmaceutski pripravak sukladno patentnom zahtjevu 11 za uporabu u liječenju krutih tumora kod ljudi i hematoloških maligniteta.13. Compounds according to any one of patent claims 1-10 or a pharmaceutical preparation according to patent claim 11 for use in the treatment of solid tumors in humans and hematological malignancies. 14. Spojevi ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 13, pri čemu se kruti tumori kod ljudi izabiru iz skupine koja sadrži karcinom dojke, karcinom želuca, kolorektalni karcinom, urotelijalni karcinom, karcinom jajnika, karcinom maternice, karcinom pluća, mezoteliom, karcinom jetre, karcinom pankreasa, i karcinom prostate.14. Compounds or pharmaceutical preparations for use according to claim 13, wherein solid tumors in humans are selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer , pancreatic cancer, and prostate cancer.
HRP20211710TT 2014-05-22 2015-05-22 Site-specific conjugation of linker drugs to antibodies and resulting adcs HRP20211710T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169493 2014-05-22
EP15724638.0A EP3151865B1 (en) 2014-05-22 2015-05-22 Site-specific conjugation of linker drugs to antibodies and resulting adcs
PCT/EP2015/061456 WO2015177360A1 (en) 2014-05-22 2015-05-22 Site-specific conjugation of linker drugs to antibodies and resulting adcs

Publications (1)

Publication Number Publication Date
HRP20211710T1 true HRP20211710T1 (en) 2022-02-04

Family

ID=50771151

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211710TT HRP20211710T1 (en) 2014-05-22 2015-05-22 Site-specific conjugation of linker drugs to antibodies and resulting adcs

Country Status (22)

Country Link
US (4) US10407743B2 (en)
EP (3) EP3151865B1 (en)
JP (2) JP6517240B2 (en)
KR (1) KR102419766B1 (en)
CN (1) CN106456794B (en)
AU (2) AU2015261768B2 (en)
CA (1) CA2947238A1 (en)
CL (1) CL2016002941A1 (en)
CY (1) CY1125232T1 (en)
DK (1) DK3151865T3 (en)
ES (1) ES2895623T3 (en)
HR (1) HRP20211710T1 (en)
HU (1) HUE056023T2 (en)
LT (1) LT3151865T (en)
MX (1) MX2016015176A (en)
MY (1) MY183480A (en)
PL (1) PL3151865T3 (en)
PT (1) PT3151865T (en)
RU (1) RU2670157C2 (en)
SG (2) SG11201609372UA (en)
WO (1) WO2015177360A1 (en)
ZA (1) ZA201607109B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
PL3056203T3 (en) 2010-04-21 2018-06-29 Syntarga B.V. Conjugates of cc-1065 analogs and bifunctional linkers
WO2015104385A2 (en) 2014-01-10 2015-07-16 Synthon Biopharmaceuticals B.V. Duocarmycin adcs showing improved in vivo antitumor activity
CA2935430C (en) 2014-01-10 2018-09-18 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in treatment of endometrial cancer
ES2895623T3 (en) * 2014-05-22 2022-02-22 Byondis Bv Site-specific conjugation of drug binders with resulting antibodies and ADCs
WO2015185142A1 (en) 2014-06-05 2015-12-10 Synthon Biopharmaceuticals B.V. Improved process for making duocarmycin prodrugs
LT3380122T (en) 2015-11-24 2021-10-11 Byondis B.V. Anti-5t4 antibodies and antibody-drug conjugates
JP2019508023A (en) * 2015-12-24 2019-03-28 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド TPBG antibody, method for preparing the same, conjugate thereof and use thereof
EA201891723A1 (en) * 2016-02-05 2018-12-28 Милленниум Фармасьютикалз, Инк. GCC-directed anti-body drug conjugates
SG11201809830WA (en) * 2016-02-12 2018-12-28 Synthon Biopharmaceuticals Bv Selective reduction of cysteine-engineered antibodies
CN109311996B (en) 2016-06-06 2023-11-28 阿布泽纳(英国)有限公司 Antibodies, uses thereof and conjugates thereof
WO2018006785A1 (en) * 2016-07-05 2018-01-11 江苏恒瑞医药股份有限公司 Egfr antibody-drug conjugate and pharmaceutical use thereof
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
RU2755899C2 (en) * 2016-10-11 2021-09-22 Байондис Б.В. Non-linear self-splitting linkers and their conjugates
ES2853999T3 (en) 2016-11-14 2021-09-20 Byondis Bv Process for the preparation of alpha, omega-diamino mono-protected alkanes
CN118027200A (en) 2016-12-09 2024-05-14 艾利妥 Anti-SIRP alpha antibodies and methods of use thereof
CN108285487B (en) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 anti-5T 4 antibody-drug conjugate and application thereof
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
JOP20190187A1 (en) * 2017-02-03 2019-08-01 Novartis Ag Anti-ccr7 antibody drug conjugates
JP7284707B2 (en) 2017-04-07 2023-05-31 ジュノー セラピューティクス インコーポレイテッド Engineered Cells Expressing Prostate-Specific Membrane Antigen (PSMA) or Modified Forms Thereof and Related Methods
RU2771310C2 (en) * 2017-05-23 2022-04-29 Байондис Б. В. Method for double conjugation for obtaining antibody-drug conjugates
US20200129633A1 (en) * 2017-06-06 2020-04-30 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
CN110891605A (en) * 2017-06-07 2020-03-17 希沃尔拜克治疗公司 Antibody conjugates of immunomodulatory compounds and uses thereof
CA3066920A1 (en) * 2017-06-16 2018-12-20 Eli Lilly And Company Engineered antibody compounds and conjugates thereof
RU2020112280A (en) * 2017-09-02 2021-10-05 Эббви Инк. ANTI-EGFR ANTIBODY-DRUG (ADC) CONJUGATES AND THEIR APPLICATION
AU2018328113B2 (en) * 2017-09-06 2023-09-07 Airway Therapeutics, Inc. Methods, compositions and cells for preparing surfactant protein D (SP-D)
EP3679066A4 (en) 2017-09-06 2021-06-09 Airway Therapeutics, Inc. Methods and compositions for preparing surfactant protein d (sp-d)
PT3713939T (en) 2017-11-24 2021-09-16 Byondis Bv Improved process for the synthesis of linker-drug vc-seco
CA3083345A1 (en) * 2017-11-27 2019-05-31 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
CN108187065B (en) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 anti-5T 4 antibody and maytansine derivative DM4 coupling complex, and preparation method and application thereof
WO2019173911A1 (en) 2018-03-13 2019-09-19 Zymeworks Inc. Anti-her2 biparatopic antibody-drug conjugates and methods of use
AU2019240403A1 (en) * 2018-03-23 2020-10-08 Seagen Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
MX2020011828A (en) 2018-05-25 2021-02-09 Alector Llc Anti-sirpa antibodies and methods of use thereof.
SG11202101428UA (en) * 2018-08-16 2021-03-30 Genmab As Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
CA3077260C (en) * 2018-08-29 2023-03-07 Remegen, Ltd. Use of anti-her2 antibody-drug conjugate in treating urothelial carcinoma
US20210393791A1 (en) * 2018-10-31 2021-12-23 Health Research, Inc. Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor
JP2022506860A (en) * 2018-11-09 2022-01-17 ビョンディス・ビー．ブイ． Filterable Duocarmycin-Containing Antibody Drug Complex Compositions and Related Methods
CN111675762B (en) * 2019-03-11 2023-12-01 凯惠科技发展(上海)有限公司 Cysteine-containing antibody, drug conjugate and application thereof
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
CA3165711A1 (en) 2020-02-06 2021-08-12 Johannes Henricus Matthias Schellens Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfate
KR20230035332A (en) 2020-07-06 2023-03-13 비온디스 비.브이. Antifolate Linker-Drug and Antibody-Drug Conjugates
CN116761824A (en) * 2021-01-18 2023-09-15 上海药明合联生物技术有限公司 Engineered anti-TROP 2 antibodies and antibody-drug conjugates thereof
WO2022214517A1 (en) 2021-04-08 2022-10-13 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
CA3223936A1 (en) 2021-06-28 2023-01-05 Ronald Christiaan Elgersma Conjugates comprising phosphoantigens and their use in therapy
CN114106180B (en) * 2021-12-13 2023-07-28 中国药科大学 Monoclonal antibody and application thereof
WO2023126297A1 (en) 2021-12-30 2023-07-06 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
WO2023222580A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies
WO2024027795A1 (en) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 Antibody-drug conjugate containing myc protein degradation agent bioactive compound, preparation method therefor, and use thereof
CN116212045A (en) * 2023-03-31 2023-06-06 温州医科大学 Novel antibody drug conjugate targeting MUC1 on cancer cell surface as well as preparation method and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
MXPA03010804A (en) 2001-06-01 2004-11-22 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof.
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
AR050642A1 (en) 2004-09-10 2006-11-08 Wyeth Corp ANTI-5T4 HUMANIZED AND CONJUGATED ANTIBODIES ANTI-5T4 ANTIBODY / CALICHEAMICINA
KR101270829B1 (en) * 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
PL1912677T3 (en) 2005-06-20 2014-03-31 Psma Dev Company L L C PSMA antibody-drug conjugates
EA016577B1 (en) * 2005-09-26 2012-06-29 Медарекс, Инк. Antibody-drug conjugates and use thereof
PL1994055T3 (en) 2006-03-10 2015-02-27 Wyeth Llc Anti-5t4 antibodies and uses thereof
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
EP2173739B1 (en) 2007-08-01 2013-07-31 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
HUE035798T2 (en) 2008-11-03 2018-05-28 Syntarga Bv Cc-1065 analogs and their conjugates
MX354143B (en) * 2009-12-02 2018-02-14 Imaginab Inc J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use.
PL3056203T3 (en) 2010-04-21 2018-06-29 Syntarga B.V. Conjugates of cc-1065 analogs and bifunctional linkers
CA2830338C (en) * 2011-04-01 2016-11-15 Wyeth Llc Antibody-drug conjugates
CA2859755C (en) * 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
ES2680153T3 (en) * 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
CN115925957A (en) 2013-02-08 2023-04-07 Irm责任有限公司 Specific sites for modifying antibodies to make immunoconjugates
CA2935430C (en) 2014-01-10 2018-09-18 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in treatment of endometrial cancer
MY177390A (en) 2014-01-10 2020-09-14 Byondis Bv Method for purifying cys-linked antibody-drug conjugates
WO2015104385A2 (en) 2014-01-10 2015-07-16 Synthon Biopharmaceuticals B.V. Duocarmycin adcs showing improved in vivo antitumor activity
ES2895623T3 (en) * 2014-05-22 2022-02-22 Byondis Bv Site-specific conjugation of drug binders with resulting antibodies and ADCs
WO2015185142A1 (en) 2014-06-05 2015-12-10 Synthon Biopharmaceuticals B.V. Improved process for making duocarmycin prodrugs
EP3197919A1 (en) 2014-09-22 2017-08-02 Synthon Biopharmaceuticals B.V. Pan-reactive antibodies to duocarmycins

Also Published As

Publication number Publication date
SG11201609372UA (en) 2016-12-29
JP2019089783A (en) 2019-06-13
DK3151865T3 (en) 2021-10-25
CN106456794B (en) 2023-02-17
AU2015261768B2 (en) 2020-03-26
CY1125232T1 (en) 2023-03-24
EP3868379A1 (en) 2021-08-25
AU2020200175A1 (en) 2020-01-30
HUE056023T2 (en) 2022-01-28
MX2016015176A (en) 2017-03-23
KR102419766B1 (en) 2022-07-13
AU2015261768A1 (en) 2016-11-03
RU2018133015A3 (en) 2021-12-07
JP2017524653A (en) 2017-08-31
US20170080103A1 (en) 2017-03-23
CA2947238A1 (en) 2015-11-26
ES2895623T3 (en) 2022-02-22
PL3151865T3 (en) 2022-01-03
CL2016002941A1 (en) 2017-12-22
SG10201913977TA (en) 2020-03-30
PT3151865T (en) 2021-11-17
KR20170005128A (en) 2017-01-11
LT3151865T (en) 2021-10-25
WO2015177360A1 (en) 2015-11-26
RU2670157C2 (en) 2018-10-18
RU2016150377A3 (en) 2018-06-25
US20210388115A1 (en) 2021-12-16
AU2020200175B2 (en) 2021-08-19
RU2016150377A (en) 2018-06-25
EP3151865A1 (en) 2017-04-12
JP6900408B2 (en) 2021-07-07
US11104968B2 (en) 2021-08-31
MY183480A (en) 2021-02-19
CN106456794A (en) 2017-02-22
US20190367999A1 (en) 2019-12-05
US10407743B2 (en) 2019-09-10
BR112016026744A2 (en) 2017-12-12
EP3151865B1 (en) 2021-09-01
RU2018133015A (en) 2018-12-04
ZA201607109B (en) 2018-05-30
EP3539544A1 (en) 2019-09-18
US20190368000A1 (en) 2019-12-05
US11136633B2 (en) 2021-10-05
JP6517240B2 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
HRP20211710T1 (en) Site-specific conjugation of linker drugs to antibodies and resulting adcs
TWI704928B (en) Anti-her3 antibody drug conjugate
HRP20181646T2 (en) Pyrrolobenzodiazepine - anti-psma antibody conjugates
HRP20231281T1 (en) Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
HRP20220133T1 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
HRP20180262T1 (en) Monoclonal anti-gt468 antibodies for treatment of cancer
HRP20211280T1 (en) Anti-5t4 antibodies and antibody-drug conjugates
JP2017171665A5 (en)
JP2018516966A5 (en)
WO2020236817A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2010535713A5 (en)
JP2012522512A5 (en)
RU2020124944A (en) ANTIBODIES AGAINST EGFR AND ANTIBODY-DRUG CONJUGATES
JP2015534577A5 (en)
RU2016129894A (en) COVALENTLY RELATED HELICAR-ANTIBODY CONJUGATES AGAINST HELICAR AND THEIR APPLICATION
RU2014101669A (en) AGENTS BINDING R-SPONDIN PROTEINS (RSPO), AND WAYS OF THEIR APPLICATION
RU2018100424A (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT TUMOR
RU2018111205A (en) THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNO CONJUGATES
JP2012100677A5 (en)
SI2533817T1 (en) Targeted alpha-particle emitting complexes comprising thorium radionuclide and hydroxypyridinone containing ligand
JP2016520082A5 (en)
JP2020502271A5 (en)
WO2018204872A3 (en) Igf-1r monoclonal antibodies and uses thereof
WO2017060322A3 (en) Ptefb-inhibitor-adc
JP2022548043A (en) Anti-oncolytic virus antigen antibody and method of use thereof